New Pharmacokinetic (PK) and Pharmacodynamic Data from Sub-Study in Phase III Trial Strengthens Scientific Basis for RenovoRx ...

New subgroup analysis shows consistent, clinically meaningful pain reduction observed from Stage 2 through Stage 4 disease, including late-stage ...

Healthcare AI is scaling faster than clinical safety. Without clinicians in the loop, companies face growing liability, ...

Michael Wang, MD, highlights several notable abstracts from ASH 2025 that collectively underscore continued progress in ...

Mental health care faces a paradox: demand has surged to record levels, yet the infrastructure supporting clinicians remains ...

Pediatric patients with autism spectrum disorder (ASD) hospitalized with acute sinusitis have increased rates of seizures, ...

Q1 2026 Earnings Call Transcript January 8, 2026 Simulations Plus, Inc. misses on earnings expectations. Reported EPS is ...

The CLL17 trial showed noninferiority of fixed-duration regimens compared to continuous BTK inhibitor therapy, highlighting ...

PDS Biotech Submits Amended Protocol for Phase 3 VERSATILE-003 Trial Constructive Type C Meeting Provides Potential Pathway to Accelerated Approval of PDS0101 PRINCETON, N.J., Jan. 09, 2026 (GLOBE NEW ...

No treatment-related adverse toxicity was observed across completed GLP studies, with consistent systemic exposure following ...

Study conducted at US sites evaluates LumeeTM in peripheral artery disease (PAD) patients BERKELEY, Calif, Dec. 11, 2025 (GLOBE NEWSWIRE) -- Profusa, Inc. (“Profusa” or the “Company”) (Nasdaq: PFSA), ...

Phase 3 SELVA study evaluating QTORIN rapamycin 3.9% anhydrous gel (QTORIN rapamycin) for microcystic lymphatic malformations (microcystic LMs) remains on track, with topline results anticipated in Ma ...